Business Context and Reporting Period
This Form 8-K Current Report, filed on November 1, 2024, by Tarsus Pharmaceuticals, Inc. (TARS), discloses a significant executive appointment and board composition change. The report details the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024, and her concurrent resignation from the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and governance changes.
Material Changes
- Executive Appointment: Dr. Elizabeth Yeu was appointed Chief Medical Officer, effective November 4, 2024.
- Board Resignation: Dr. Yeu resigned from the Board of Directors and all associated committees effective November 4, 2024, following her appointment as an officer.
- Compensation Structure:
- Annual Base Salary: $480,000.
- Signing Bonus: $25,000 (cash, payable within 30 days).
- Annual Incentive Bonus: Target of 45% of base salary.
- Restricted Stock Units (RSUs): 27,278 shares granted, vesting 25% annually over four years (Dec 15, 2025–2028).
- Stock Options: 41,074 shares granted, with 25% vesting after 12 months and the remainder vesting monthly over the subsequent 36 months.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of market risks. It does disclose specific severance and change-in-control provisions:
- Severance: In the event of involuntary termination within a specific window surrounding a Change in Control, Dr. Yeu is eligible for 12 months of base salary, continued benefits, and a lump sum bonus equal to 100% of her target bonus plus a prorated portion.
- Accelerated Vesting: Under the same Change in Control conditions, unvested RSUs and Options would accelerate.
Investor Verification Checklist
- Verify the impact of Dr. Yeu's transition from Board member to executive officer on the Company's governance structure.
- Review the total equity dilution impact of the 27,278 RSUs and 41,074 stock options granted.
- Confirm the terms of the Executive Severance and Change in Control agreement regarding potential payouts in a merger or acquisition scenario.
- Check the Company's upcoming 10-K filing for the full text of the Yeu Offer Letter as referenced in the report.